



ASX ANNOUNCEMENT

2 September 2026

Vitrafy Enters U.S. Cell & Gene Therapy Market with Charter Medical Agreement

Vitrafy Life Sciences Ltd ("**Vitrafy**" or "**the Company**") (ASX: VFY) today announced an agreement with Charter Medical, LLC ("**Charter Medical**") to deploy its next-generation cryopreservation ecosystem in its Innovation Hub. The agreement marks Vitrafy's first entry into the U.S. cell and gene therapy ("**CGT**") market.

Highlights

- Vitrafy to install its cryopreservation ecosystem at Charter Medical's North Carolina Innovation Hub, supporting cryopreservation and freeze curve optimisation for Charter Medical's Cell and Gene Therapy customers.
- Charter Medical is an established supplier of consumables, bags and services to the Contract Development and Manufacturing Organisation ("**CDMO**") and CGT manufacturing sectors, with more than 30 years' experience serving industry-leading biopharmaceutical companies.
- Charter Medical provides cryopreservation study services to CGT customers, including many of the sector's leading developers and manufacturers — through this agreement, Vitrafy aims to scale and provide value across that customer base, which includes therapy developers and biopharmaceutical companies.

Overview

Vitrafy today announced an agreement to install its cryopreservation ecosystem — comprising one Guardian cryopreservation freezing unit and the LifeChain™ software platform — at Charter Medical's Innovation Hub.

Charter Medical will use Vitrafy's technology ecosystem to support cryopreservation and freeze-curve optimisation studies for its CGT customers. Freeze-curve optimisation is a challenge in cell and gene therapy process, with improvements in cell recovery critical to advancing clinical outcomes and reducing cost.

The Guardian unit is designed to deliver controlled, reproducible freeze profiles across a wide range of cell lines, while LifeChain™ is set up to capture processing data, to deliver improved cryopreservation protocols and outcomes for Charter Medical's operations.

The Agreement

This is Vitrafy's first agreement in cell and gene therapy, and its first in North America — a market with over thousands of participants registered contract manufacturers across the pharmaceutical sector.



The agreement will span an initial 6-month term with deployment to occur in 2H FY2027. No revenue will be generated across the initial term agreed between the partners.

This agreement demonstrates the applicability of the Company's ecosystem beyond blood market activities, in a segment where the value of preserved biomaterial is high and cryopreservation performance is a recognised critical requirement for many manufacturers.

Charter Medical's focus is on demonstrating improved outcomes for its single-use products, while the Vitrafy ecosystem provides the freeze performance and data required to evidence them. This deployment could open a pathway to further pipeline development and longer-term commercial relationships across the U.S. CGT market¹.

About Charter Medical

Charter Medical, LLC specialises in designing and manufacturing standard and custom single-use technologies (including packaging consumables) for the advanced therapy, bioprocessing, and blood management markets. For more than 30 years, Charter Medical—an ISO 13485/NSAI certified and FDA registered company—has been providing high-quality, innovative solutions that continue to help industry-leading biopharmaceutical companies bring advanced, life-saving therapies to market.

Charter's Innovation Hub, established in 2024, is located in downtown Winston-Salem's Innovation Quarter — a mixed-use innovation district anchored by Wake Forest University School of Medicine and home to the RegenMed Hub, one of the more active concentrations of regenerative medicine and cell therapy activity in the United States. The Innovation Hub houses laboratory space dedicated to single-use freezing, transportation and protection studies supporting the biopharmaceutical industry's cold chain

Charter Medical is part of the Solesis family of companies.

Outlook

Vitrafy Managing Director and CEO, **Brent Owens**, commented:

"This agreement is a significant milestone as our first product deployment in cell and gene therapy, incorporating Vitrafy's cryopreservation hardware and LifeChain™ software platform from the outset.

Freeze curve optimisation across different cell lines is a real and unresolved problem for cell and gene therapy manufacturers, and one our ecosystem is built to solve. Charter Medical has supplied the advanced therapy sector for more than 30 years and works with the CDMOs and therapy developers we are targeting, so this deployment puts our technology directly in front of those customers with a trusted market leader."

- ENDS -

¹ As with other process equipment used in CGT manufacturing, therapy developers incorporate the ecosystem into their own FDA submissions, including to CBER, ahead of any human use.



This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Tim Sharpe

Vice President of Strategy & Corporate Development

investors@vitrafy.com

About Vitrafy

Vitrafy has developed a proprietary cryopreservation ecosystem including the Guardian cryopreservation freezing unit, and LifeChain™, a cloud-based software platform, to offer an integrated cryopreservation solution. The Vitrafy ecosystem delivers a new standard of cryopreservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the collection, storage and delivery process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets.

Vitrafy is headquartered in Melbourne, Australia and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit vitrafy.com.

For personal use only